Brokerages Set ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) PT at $105.83

Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) have earned a consensus rating of “Moderate Buy” from the eight ratings firms that are covering the stock, Marketbeat reports. Four equities research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $105.8333.

A number of equities analysts recently weighed in on the company. Zacks Research cut ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 14th. Guggenheim dropped their price objective on ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating on the stock in a report on Monday, August 10th. Canaccord Genuity Group cut their price objective on ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating for the company in a research report on Monday, August 10th. Weiss Ratings downgraded ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, August 11th. Finally, Wall Street Zen downgraded ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 8th.

Insider Activity at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, CFO Stephen P. Carey sold 2,850 shares of the company’s stock in a transaction on Wednesday, July 29th. The shares were sold at an average price of $81.36, for a total transaction of $231,876.00. Following the completion of the transaction, the chief financial officer directly owned 174,693 shares in the company, valued at approximately $14,213,022.48. This represents a 1.61% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Ori Gutwerg sold 3,162 shares of the company’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $77.00, for a total transaction of $243,474.00. Following the transaction, the senior vice president owned 75,534 shares of the company’s stock, valued at $5,816,118. This represents a 4.02% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 18,987 shares of company stock worth $1,546,405 in the last quarter. 8.10% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of ANIP. KBC Group NV purchased a new stake in ANI Pharmaceuticals during the 1st quarter worth approximately $28,000. Advisors Asset Management Inc. purchased a new position in shares of ANI Pharmaceuticals in the first quarter valued at approximately $28,000. Hantz Financial Services Inc. boosted its stake in shares of ANI Pharmaceuticals by 70.3% in the fourth quarter. Hantz Financial Services Inc. now owns 603 shares of the specialty pharmaceutical company’s stock worth $48,000 after acquiring an additional 249 shares during the last quarter. Kemnay Advisory Services Inc. acquired a new stake in shares of ANI Pharmaceuticals in the fourth quarter worth approximately $48,000. Finally, State of Wyoming purchased a new stake in shares of ANI Pharmaceuticals during the second quarter worth approximately $50,000. 76.05% of the stock is owned by hedge funds and other institutional investors.

ANI Pharmaceuticals Stock Down 2.5%

ANIP stock opened at $75.35 on Wednesday. The firm has a market cap of $1.73 billion, a PE ratio of 16.24 and a beta of 0.44. The company has a debt-to-equity ratio of 0.99, a quick ratio of 2.41 and a current ratio of 2.91. The firm’s fifty day moving average is $80.36 and its 200 day moving average is $78.88. ANI Pharmaceuticals has a one year low of $70.15 and a one year high of $99.50.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings data on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share for the quarter, beating analysts’ consensus estimates of $2.04 by $0.17. ANI Pharmaceuticals had a net margin of 11.07% and a return on equity of 27.37%. The company had revenue of $266.04 million during the quarter, compared to analysts’ expectations of $260.13 million. During the same quarter in the previous year, the company earned $1.80 earnings per share. The firm’s revenue for the quarter was up 25.8% on a year-over-year basis. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. On average, research analysts forecast that ANI Pharmaceuticals will post 7.83 EPS for the current year.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.